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ABSTRACT
The explosive epidemics of diabetes and obesity as well as an aging population have led to cardiovascular diseases as the 
leading cause of world-wide morbidity and mortality beyond cancer. The recent introduction of drug-eluting stents and me-
dications such as statins, dual anti-platelet therapy, and angiotensin converting enzyme inhibitors has dramatically improved 
clinical outcomes in patients with cardiovascular diseases. However, mortality is still increasing despite state-of-the-art ther-
apeutics, as current diagnostic and therapeutic strategies against cardiovascular disease center on “locking the barn door after 
the horse has been stolen”. Novel diagnostic solutions that identify individuals at risk before the disease is overt are needs. Im-
aging approaches that visualize molecular targets rather than anatomical structures aim to illuminate vital molecular and 
cellular aspects of atherosclerosis biology in vivo. Recent technological advances in small animal imaging systems and dedi-
cated targeted/activatable molecular imaging probes have positioned molecular imaging to greatly impact atherosclerosis im-
aging in the next decade. However, several issues must be addressed before its clinical translation. (Korean Circ J 2011;41: 
497-502)
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Introduction
Percutaneous coronary intervention (PCI) reduces the in-
cidence of death and myocardial infarction (MI) in patients 
with acute coronary syndrome who harbor vulnerable athero-
sclerotic plaques in coronary arteries.
1-3) However, PCI as ini-
tial management fails to reduce the risk of death, MI, or other 
major cardiovascular events when added to optimal medical 
therapy in those with stable coronary artery disease who have 
cool-down coronary plaques with lower probability of erup-
tion but anatomically flow-limiting stenoses.
4) Furthermore, 
autopsy findings show that the majority of vulnerable pla-
ques are usually <50% diameter stenosis.
5) In this regard, 
imaging tools that sense molecular and cellular processes 
within atherosclerotic plaques may be a better and/or com-
plimentary tool than coronary lumenography assessing ana-
tomical severity. Molecular imaging of coronary or cerebral 
arteries in addition to a current systemic risk evaluation such 
as the Framingham risk score provide a better regional and 
systematic ischemic event-risk portfolio. 
The world is about to experience a demographic revolution. 
First, there is an exponential increase in patients with obesi-
ty and diabetes. Second, the world will become a super-aged 
society within the next two decades. Thus we can expect a gr-
eater prevalence of cardiovascular disease and greater car-
diovascular mortality. In fact, cardiovascular disease is the 
number one killer in the world, despite state-of-the-art diag-
nostics and therapeutics. These conditions suggest that we 
must shift the mainstream of translational cardiovascular re-
search to prior recognition of plaque rupture before patients 
develop acute coronary syndrome and sudden death.
Numerous molecular imaging approaches, which reveal 
the underlying molecular or cellular basis of atherosclerosis, 
have been introduced into the field of cardiovascular rese-
arch in the past 10 years, using small animal imaging systems 
and dedicated targeted/activatable molecular imaging pro-
bes.
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high-risk atherosclerotic plaques have translated clinically. 
In this review, we will focus on the clinical translatability of 
molecular imaging of atherosclerosis. First, ideal targets for 
imaging high-risk atherosclerotic plaques will be briefly dis-
cussed. Next, we will present which modality is most closely 
associated with clinical translation in the near future while con-
sidering previous validation in humans, and potential safety 
concerns regarding the use of molecular imaging probes. 
Traditional Imaging Targets
Molecular imaging has evolved with the introduction of a 
variety of contrast agents that target specific cellular or mole-
cular processes of disease relevance. In accordance with the 
imaging modalities and techniques being developed, contrast 
agents for tracking potentially important components of ath-
erosclerotic disease have targeted various stages of atheroge-
nesis (Fig. 1). For the past decade, imaging probes targeting 
adhesion molecules such as vascular cell adhesion molecule-1 
(VCAM-1), oxidized low density lipoprotein (LDL), apopto-
sis, proteases such as matrix metalloproteinases (MMPs), ca-
thepsins or cysteine protease, and macrophages have been ex-
tensively applied to detect plaque inflammation or vulner-
ability.
8) First, the advantages and disadvantages of several 
traditional molecular imaging agents will be discussed. Then, 
new emerging molecular targets will be presented. Target se-
lection is crucial for success, because most imaging targets are 
located in deep organs and are frequently present at very low 
concentrations. 
Macrophages as an imaging target
Because macrophages are involved in all stages of athero-
sclerosis, including foam cell formation, plaque progression, 
and, ultimately, plaque disruption and thrombus formation,
9) 
inflammatory cells residing in plaque such as macrophages 
and foam cells are excellent imaging targets. Small-animal 
aortic magnetic resonance imaging (MRI) combined with 
dextranated ultrasmall superparamagnetic iron oxide nano-
particles (USPIO) has been most frequently employed to vi-
sualize atheroma-related macrophages.
10) USPIOs are engulf-
ed by macrophages in vivo, followed by a detectable decrease 
in the T2/T2* signal in proportion to the degree of atherosc-
lerotic plaque inflammation, as shown in human studies.
11) 
Our lab has also successfully imaged cellular inflammation in 
murine atherosclerosis using pegylated, silica-coated iron ox-
ide nanoparticles (Fig. 2).
12) Recently, 
18F-fluorodeoxyglucose 
(FDG) positron-emission tomography (PET) has emerged as 
a surrogate imaging biomarker to report plaque macrophage 
activity and has been used to monitor anti-atherosclerosis th-
erapy (Fig. 3).
13)14) FDG-PET will be promising when suc-
cessfully extending its application into the prediction of pla-
que rupture and clinical events. Although macrophages are 
an ideal imaging target in mouse models of atherosclerosis, 
major differences in lesion composition between mice and 
humans are apparent.
15) Although inflammation is the most 
abundant plaque component in mice, it constitutes only 2-5% 
of total lesion volume in humans.
16) Currently, the most fre-
quently used mouse models of atherosclerosis are apoE
-/- mice 
or LDL receptor-deficient mice, similar to the human model 
of familial hypercholesterolemia, a rare form of human ath-
erosclerosis. These mice models develop atheromas mainly 
composed of foam cells and proliferating smooth muscle cells 
without a necrotic core or fibrous cap, typical of vulnerable 
human atherosclerotic plaques. Thus, macrophages may not 
Fig. 1. Development of an atherosclerotic lesion and specific imaging targets at different stage of atherogenesis. The main cellular or mo-
lecular processes involved in each stage of atherosclerosis are presented. Potential molecular imaging targets at different stages are also 
listed.
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be a good candidate for molecular imaging of high-risk ath-
erosclerotic plaques. 
Protease as an imaging target
After recruitment, macrophages scavenge lipids, secrete 
cytokines that further amplify inflammation, and produce 
proteases such as MMPs and cathepsins. In concert with the 
phagocytic function of inflammatory cells, proteases destabi-
lize plaque by damaging the extracellular matrix and thin-
ning the fibrous cap.
17) Thus , augmented protease activity wi-
thin the fibrous cap is a key feature of high-risk plaques.
18) Pro-
teases are targeted with two major strategies. Nuclear imaging 
probes, which could be used for noninvasive coronary imag-
ing, are based on small-molecule protease inhibitors. An al-
ternative approach uses optical imaging agents, adopting a 
quenching-dequenching strategy to generate a high signal-
to-noise ratio in vivo
19) The enzymes cleave defined peptide 
sequences, liberate the attached fluorochromes, and, thereby, 
render them fluorescent. Thus, activatable optical imaging ag-
ents have a low background fluorescence signal, in contrast 
with traditional targeted near-infrared fluorescence (NIRF) 
agents. Another advantage of activatable imaging agents is 
the potential to image and quantify protease activity, rather 
than its presence within plaques. However, targeted nuclear 
imaging probes need further validation for clinical transla-
tion. As in the molecular imaging of oncology, it is still un-
clear whether protease-targeted PET imaging can replace 
FDG-PET in patients with atherosclerosis. Activatable NIRF 
agents together with clinical type intravascular NIRF-sensing 
catheters can be used to detect protease activity in human 
coronary arteries.
20) Additionally, combining an NIRF-sensing 
catheter with intravascular ultrasound or optical coherence 
tomography will strengthen its clinical translation.
21) 
Promising Imaging Targets
Apoptosis
A key element of vulnerable atherosclerotic plaques is a 
large necrotic core. Necrotic core is mainly formed by the com-
bination of apoptosis of advanced lesional macrophages and 
defective efferocytosis in advanced plaques.
22) Prolonged en-
doplasmic reticulum stress and other factors such as oxida-
tive stress and death receptor activation provoke apoptosis in 
macrophage foam cells.
23) These apoptotic cells are not effec-
tively cleared by macrophages, due to defective efferocytosis 
in advanced atherosclerotic plaques, leading to secondary 
cellular necrosis. Secondary necrosis over time contributes to 
the formation and growth of a necrotic core.
24) Thus, apopto-
sis is a fascinating imaging target for plaque vulnerability. In-
deed, a number of apoptosis imaging approaches have been 
implemented and have been applied in humans.
25) Although 
99mTC- annexin A5 imaging of inflamed carotid plaques is 
clinically feasible, its low resolution and specificity may be a 
hurdle to overcome, in addition to imaging difficulties of the 
coronary tree such as small plaque size and cardiac and re-
spiratory motion. 
Neoangiogenesis 
The developmental stage of a fibroatheroma is consistently 
associated with centripetal neoangiogenesis from the adven-
titia toward the plaque.
26) An intraplaque hemorrhage frequ-
ently occurs, because neo-capillaries in atheromas are imma-
ture and leaky, leading to sudden expansion of the necrotic 
core and increasing plaque vulnerability.
27) Thus, intraplaque 
neovascularization and hemorrhage are postulated to play a 
major role in plaque progression, leukocyte infiltration, and 
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Fig. 3. Effect of simvastatin on fluorodeoxyglucose (FDG) uptake 
into atherosclerotic plaques. Diet alone does not have an effect on 
FDG uptake into carotid arteries. In contrast, simvastatin signifi-
cantly attenuated FDG uptake into carotid arteries.
9)
Fig. 2. Upper right panel (B) shows a dark signal in the wall of an 
apoE
-/- mouse aorta after an injection of silica-coated iron oxide 
nanoparticles compared with a precontrast MRI (A). Confocal mi-
croscopy shows accumulation of iron oxide nanoparticles in the 
aorta of a 30-week-old apoE
-/- mouse. Most nanoparticles are not-
ed in the macrophage-rich plaque area (C and D).
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high-risk plaque formation. Molecular imaging agents for 
plaque neoangiognesis usually target αVβ3-integrin, a key 
mediator of angiogenesis. 
18F-RGD is a promising peptide 
tracer for PET imaging of intraplaque neovascularization, 
which binds with high affinity to αVβ3-integrin. 
18F-RGD has 
been extensively validated for use in oncology. However, the 
utility of 
18F-RGD PET for imaging vascular inflammation 
and plaque angiogenesis has not been completely clarified. In-
depth translational research will clarify the clinical feasibility 
of 
18F-RGD. Recently, we verified the efficacy of apoptosis and 
neoangiogenesis as potential targets of clinical molecular im-
aging in the carotid atheromata of apoE
-/- mice using intravi-
tal two-photon microscopy (Fig. 4). 
Considerations for Clinically  
Translating Atherosclerosis  
Molecular Imaging 
Several issues must be considered to translate molecular ath-
erosclerosis imaging for clinical use. First, it must be deter-
mined which modality is the best fit for near-term clinical 
translation Second, we have limited knowledge on the fate 
of vulnerable atherosclerotic plaques. It is still not completely 
understood how a stable plaque becomes a high-risk plaque 
that ultimately ruptures and creates occlusive or nonocclusive 
thrombi in the coronary arteries. It is also yet to be investigat-
ed whether plaque vulnerability is short-lived or fairly long-
lasting. How many vulnerable plaques exist in an individual 
patient? Will all vulnerable plaques lead to acute coronary 
syndrome or will a vulnerable plaque with particular charac-
teristics be mainly responsible for the event? Because of the 
lack of a typical animal model with the human form of vulner-
able atherosclerotic plaques, the natural history of plaque pro-
gression and the fate of vulnerable plaques are poorly under-
stood.
15) Thus, once a molecular imaging tool is available in 
the clinic, there will be significant progress in clarifying the 
life history of plaques, but significant amounts of clinical data 
using molecular imaging tools will be needed to adopt routine 
imaging. 
Recent advances in small-animal imaging technologies, su-
ch as fluorescence imaging, bioluminescence imaging, ultra-
sound, micro-PET, micro-single photon emission computed 
tomography (SPECT), micro-computed tomography (CT), 
and high-field (4.7T or 9.4T) small-animal MRI as well as 
the availability of dedicated imaging probes targeting mole-
cular or cellular processes have positioned molecular imag-
ing to greatly impact atherosclerosis imaging in the next de-
cade. Clinical translation of these advances of small animal 
atherosclerosis molecular imaging is greatly anticipated with 
the introduction of human imaging platforms or imaging pro-
bes. However, several factors must be considered for imaging 
coronary plaques. The coronary arteries are usually 2.5-3.5 
mm in diameter; thus, their plaques are too small to be imag-
ed well enough to show molecular signals in addition to anato-
my. In addition, coronary plaques are not in a static condition 
but move quickly with the heart and respiration. All of these 
conditions require imaging tools with high spatial and tem-
poral resolution. In this regard, MRI shows promise for mo-
lecular imaging of vulnerable plaques in coronary arteries. 
Indeed, many investigators have explored the applicability of 
molecular MRI for atherosclerosis to detect macrophage ac-
tivity, apoptosis, and adhesion molecules within plaques, mo-
stly using gadolinium chelates (T1 agents) or iron oxide na-
noparticles (T2/T2* agent). However, MRI must overcome the 
major obstacle of lower imaging sensitivity compared with 
that of PET, which requires only several nanograms of PET 
agent for molecular imaging (Table 1). However, PET has 
intrinsic weaknesses for applications in cardiovascular molec-
ular imaging because of its limited spatial resolution (clinical-
ly, 4-10 mm; small-animal imaging, 1-2 mm). We will consid-
er this imaging modality issue in detail in the next section.
Magnetic resonance imaging
MRI as a molecular imaging modality has many strengths; 
its remarkable spatial resolution, of which 3T MRI provides 
10 to 100 μm resolution, lack of radiation exposure, and its 
Fig. 4. High-resolution in vivo fluorescence molecular imaging of intraplaque neoangiogenesis and apoptosis in carotid atheroma of apoE
-/- 
mice. After injecting angiogenesis- and apoptosis-targeting molecular imaging agents, intravital two-photon microscopy of carotid athero-
mata in a 34 week-old apoE
-/- mouse revealed discrete plaque-specific neoangiogenesis (middle) and apoptosis (right).Byung-Hee Hwang, et al.   501
unique ability to combine anatomical, functional, and mole-
cular information. In contrast, the low imaging sensitivity of 
MRI is a fundamental weakness for clinical translation. Low 
imaging sensitivity means that MRI requires a large volume 
of agent for molecular imaging, which is associated with to-
xicity. Molecular MRI adopts specialized imaging agents that 
have a relatively larger diameter than conventional gadolinum 
chelate, because a longer circulation time is mandatory to 
bind to tissue targets, in addition to the T1 or T2/T2* short-
ening effect. Thus, most imaging agents for molecular MRI 
are nanometer-sized. 
However, knowledge is incomplete regarding nanoparticle 
toxicity, biodistribution, excretion, and pharmacokinetics. 
The Food and Drug Administration (FDA) applies the same 
degree of regulatory oversight for nanoparticulate imaging 
agents as new drugs. In the near term, we are not ready to in-
travenously inject nanoparticulate molecular imaging agents 
into humans. Further efforts are required to realize molecular 
MRI as routine practice
Positron-emission tomography
Currently, PET and SPECT are the most translatable non-
invasive molecular imaging platforms because of the avail-
ability of existing clinical scanners, the availability of versatile 
radiochemistry options, and the ongoing development of new 
imaging agents, which only need to be administered in a 
small, nonpharmacological dose (nanograms) for highly sen-
sitive imaging. Although PET is the most sensitive and quan-
titative modality, it has limited spatial resolution and, unfor-
tunately, physical constraints make it unlikely that PET spatial 
resolution will improve further. Thus, a combination of SPE-
CT/PET with CT images or PET with MRI is being studied 
to further enhance anatomic localization. We identified the 
superiority of FDG PET/CT of carotid arteries compared to 
ultrasound for detecting plaque inflammation (Fig. 5). How-
ever, FDG PET/CT has several inherent weaknesses for use 
as a routine imaging technique. It is not specific to high-risk 
plaques and is heavily influenced by other factors such as 
fasting, stress, or medications. Additionally, the myocardium 
avidly takes up FDG, producing high background signals. 
PET imaging of coronary plaques has overcome the motion 
artifact and partial volume effects due to the small vessel size 
of coronary arteries. Radiation exposure is another concern for 
routinely adopting PET imaging. 
Conclusion
In addition to traditional imaging targets such as macro-
phages, proteases, or adhesion molecules and promising tar-
gets including apoptosis and neo-angiogenesis, further adv-
ances in our understanding of atherosclerosis biology hold 
promise for identifying new targets. In the near future, mo-
lecular PET/CT using targeted 
18F or 
68Ga will be clinically in-
troduced, mainly because of less concern for adverse contrast 
agent effects, compared with MRI, CT, or sonography. Fluo-
rescence molecular imaging may be clinically introduced in 
the form of an intravascular NIRF-sensing catheter with the 
use of FDA-approved indocyanine green. The current rapid 
advances in translational molecular imaging research may 
fundamentally shift the diagnostic and therapeutic paradigm 
in the field of cardiovascular disease. 
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